The Alliance for Safe Biologic Medicines was organized to serve as an authoritative resource center of information for the general public, as well as the healthcare and health policy communities, on the issues surrounding biologic medications.

Each state will be considering or introducing legislation to address what an FDA determination on interchangeability will mean for state substitution policies.  While the ultimate goal is to find a balance between producing economical drugs and respecting the drug-discovery process, patient safety should be paramount.

We are particularly concerned about how state laws and regulations will impact the doctor-patient relationship. Doctors and patients should be able to carefully choose the best course of treatment rather than have legislators and regulators decide for them. The path state governments decide to pursue in approving biosimilars should reinforce this principle.

As such, a number of local organizations have joined together to ensure that state biosimilar interchangeability and substitution issues are not implemented in ways that negatively impact patient care or the role of the physician in that process.

Please check back for more information on our membership and activities.

• Archive

  Op-Ed: Protect Patients with Open Communication

  October 6, 2016

  On September 30th, An op-ed appeared in the Detroit News, authored by Marcia Horn, President and CEO of the International Cancer Advocacy Network (ICAN), an ASBM Steering Committee member. Ms. Horn discusses how legislation permitting biosimilar substitution could help Michigan patients. Similar legislation has been passed in 25 states and Puerto Rico. A key provision […]

  Michigan House To Take Up Biosimilars Bill

  October 9, 2015

  The Committee on Health Policy is shortly expected to begin hearings on House Bill 4812. HB 4812 was introduced by Rep. John Bizon, a physician, and contains many valuable protections such as patient notification, pharmacist-physician communication within 5 days of a substitution, and DAW (dispense as written) authority for the prescribing physician. The bill has […]

  20th Annual Symposium on Molecular Pathology

  July 14, 2011

  Clinical Applications of Genomic Medicine September 21-22, 2011 Somerset Inn Troy, MI Read More

  20th Annual Symposium on Molecular Pathology

  July 14, 2011

  Clinical Applications of Genomic Medicine September 21-22, 2011 Somerset Inn Troy, MI Read More

  2011 MichBio Expo & Conference

  July 14, 2011

  November 2-3, 2011 DeVos Place Convention Center Grand Rapids, MI Read More

  July 14, 2011

  MichBio Michigan Biosciences Legislative Caucus Michigan Department of Community Health Michigan House of Representatives Michigan Senate Task Force and House Subcommittee Michigan State Legislature Michigan State Medical Society Michigan State Senate Office of Governor Rick Snyder

  Michigan Senate Task Force and House Subcommittee

  July 14, 2011

  A growing awareness by state legislators of the industry’s economic growth potential culminated in 2009 in the formation of a Task Force on Biotechnology as part of the Senate’s Economic Development & Regulatory Reform Committee as well as a House Subcommittee focused on biosciences as part of the Committee on New Economy & Quality of […]

  Michigan Biosciences Legislative Caucus

  July 14, 2011

  MichBio was instrumental in forming the State Biosciences Legislative Caucus (BLC) that serves to educate legislators on biotechnology issues. In so doing, we believe that we can ultimately impact policies and programs to benefit the state’s biosciences industry and help make Michigan a leader in this market sector. The BLC is a bipartisan, bicameral body […]

  2010 MichBio Annual Report

  July 14, 2011

  MichBio leads advocacy efforts on behalf of the biosciences community, representing members’ interests on critical issues at the local, state and federal levels.  In addition, through its affiliation with the Biotechnology Industry Organization (BIO), MichBio regularly attends BIO-organized efforts to positively impact key votes on biotechnology-related legislation. Read More

  2010 MichBio Annual Report

  July 14, 2011

  MichBio leads advocacy efforts on behalf of the biosciences community, representing members’ interests on critical issues at the local, state and federal levels.  In addition, through its affiliation with the Biotechnology Industry Organization (BIO), MichBio regularly attends BIO-organized efforts to positively impact key votes on biotechnology-related legislation. Read More